Labgenomics Co

Labgenomics Co Stock-Based Compensation

The Stock-Based Compensation (SBC) of Labgenomics Co (084650.KQ) as of Nov 5, 2026 is 7.25 M KRW. In the previous year, Stock-Based Compensation (SBC) was 501.31 M KRW — a change of -98.55% (lower).

Stock-Based Compensation

7.25 MKRW

YoY

-98.55%

Last updated:

Stock-Based Compensation (SBC) of Labgenomics Co is 2025 7.25 M KRW. Stock-Based Compensation (SBC) of Labgenomics Co was 2024 501.31 M KRW. It decreases by -98.55% lower compared to the previous year.

The Labgenomics Co Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2021
31.78 M KRW
Jan 1, 2022
47.94 M KRW
Jan 1, 2023
16.15 M KRW
Jan 1, 2024
501.31 M KRW
Jan 1, 2025
7.25 M KRW
The Labgenomics Co Stock-Based Compensation history
YEARStock-Based CompensationYoY
7.25 MKRW-98.55%
501.31 MKRW+3,003.32%
16.15 MKRW-66.30%
47.94 MKRW+50.83%
31.78 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Labgenomics Co Stock analysis

What does Labgenomics Co do? LabGenomics Co., Ltd. generates revenue through the provision of in vitro diagnostic (IVD) products and services. The company offers general diagnostic check services, molecular diagnostic check services, and research and development services, alongside IVD products such as DNA chips and PCR kits. Its diagnostic services include examinations for breast cancer and colorectal cancer, while its biosensor solutions target point of care testing (POCT). Additionally, LabGenomics sells healthy food as part of its product portfolio. The primary buyers of LabGenomics' services are healthcare institutions requiring diagnostic support, including hospitals and clinics. The company's molecular diagnostic services and cancer examinations are particularly sought after by medical facilities focused on specialized testing. Healthcare providers also purchase its biosensor solutions for immediate testing at the point of care. LabGenomics' product segments include IVD services, IVD products like DNA chips and PCR kits, cancer examination services, and healthy food. The company's molecular diagnostic services and cancer testing are key revenue drivers, while its biosensor for POCT and healthy food offerings serve complementary market segments. Labgenomics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Labgenomics Co stock

Stock-Based Compensation (SBC) of Labgenomics Co is 7.25 M KRW in 2025.

Stock-Based Compensation (SBC) of Labgenomics Co changed from 501.31 M KRW to 7.25 M KRW, representing a -98.55% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Labgenomics Co since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Labgenomics Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Labgenomics Co

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Labgenomics Co